DOM FIGURE 5 Gene expression of Prkaa1 and Prkaa2 is increased by substrate challenge in hepatocytes from vehicle treated mice ex vivo and by chronic treatment with AZD1656 (3mg/kg) for 8 wk.
mRNA levels for Prkaa1 (AMPK-alpha1) and Prkaa2 (AMPK-alpha2) were determined in the experiments described in Fig. 4 in hepatocytes isolated from mice treated for 8-weeks with vehicle or AZD1656 (1 or 3 mg/kg) and then challenged for 4h with the substrates indicated as in Fig. 4I-P. A-B. mRNA levels for Prkaa1 and Prkaa2 normalized to hepatocytes from vehicle treated mice in basal conditions (5mM glucose). C-D. mRNA levels of Prkaa1 and Prkaa2 normalized to the respective controls at 5mM glucose. Means ± SEM, n=4, *P< 0.05 vs respective control (5G); # P < 0.05 vs respective untreated (0 mg/kg).
MICA: Exploring a new perspective on the mechanism of action of Glucokinase Activators in liver, a preclinical study
Medical Research CouncilFind out more...